Dolby Laboratories, Inc.

Listed Company

DLBCIK 0001308547NYSELarge AcceleratedPatent Owners & LessorsDelawareFY ends Sep 27

Period

FY 2025

Revenue

$1.35B

Net Income

$255.02M

Total Assets

$3.23B

Equity

$2.62B

Shares Out

—

Op. Cash Flow

$472.20M

Business

Dolby Laboratories, Inc. develops and licenses audio and video technologies that improve entertainment capture, transmission, and playback across creative and consumer ecosystems. It offers branded audio and imaging technologies (including Dolby Atmos, Dolby Vision, Branded Audio Codecs), patent licensing, cinema hardware and services, and a SaaS real‑time engagement product (Dolby OptiView). Its business is organized around branded technology licensing, patent licensing (including participation in patent pools), cinema products and services, and software offerings. Dolby distributes its technologies globally through direct licensing to semiconductor and OEM manufacturers, patent pools, exhibitors, and enterprise SaaS channels.

Summary from filing dated 2025-11-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Revenue	1,349	1,274	1,300	1,254	1,281
Total cost of revenue	160	140	153	141	130
Gross margin	1,189	1,133	1,147	1,112	1,151
Research and development	262	264	272	261	254
Sales and marketing	361	334	354	359	333
General and administrative	287	270	258	275	224
Restructuring charges	15	6	47	11	10
Total operating expenses	924	875	931	906	807
Operating income	265	258	216	207	344
Interest income/(expense), net	15	34	28	6	3
Other income/(expense), net	23	20	6	3	7
Total other income	39	54	34	9	10
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	303	312	250	215	355
Provision for income taxes	−47	−48	−48	−31	−37
Net income including controlling interest	256	264	202	184	318
Net income attributable to Dolby Laboratories, Inc.	255	262	201	184	310
Basic (usd per share)	2.66	2.74	2.1	1.84	3.07
Diluted (usd per share)	2.62	2.69	2.05	1.81	2.97
Basic (shares)	96	96	96	100	101
Diluted (shares)	97	97	98	102	105
Cash dividend declared per common share	1.32	1.23	1.11	1.02	0.91
Cash dividend paid per common share	1.32	1.2	1.08	1	0.88

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash and cash equivalents	702	482	745	620	1,225
Restricted cash	91	96	73	8	8
Short-term investments	703,000	0	139	189	39
Accounts receivable, net of allowance for credit losses of $7,221 and $5,361	331	315	262	244	233
Contract with Customer, Asset, after Allowance for Credit Loss, Current	181	197	182	176	182
Inventories	30	34	36	24	11
Prepaid expenses and other current assets	52	70	51	50	63
Total current assets	1,388	1,194	1,488	1,311	1,760
Long-term investments	80	89	98	103	63
Property, plant and equipment, net	471	479	482	513	534
Operating lease right-of-use assets	33	39	40	47	67
Intangible assets, net	397	435	167	112	123
Goodwill	530	533	408	365	341
Deferred taxes	214	220	202	184	156
Other non-current assets	114	121	95	55	61
Total assets	3,228	3,110	2,980	2,690	3,106
Accounts payable	18	17	21	14	18
Accrued liabilities	369	348	351	230	263
Income taxes payable	9	9	5	1	1
Contract liabilities	31	32	32	19	18
Operating lease liabilities	10	12	14	13	15
Total current liabilities	438	418	422	278	316
Non-current contract liabilities	30	35	40	23	24
Non-current operating lease liabilities	28	35	37	38	57
Other non-current liabilities	100	136	108	100	105
Total liabilities	596	623	608	439	501
Retained earnings	2,635	2,496	2,392	2,298	2,608
Accumulated other comprehensive income	−13	−19	−37	−52	−10
Total stockholders equity Dolby Laboratories, Inc.	2,623	2,477	2,355	2,246	2,598
Controlling interest	9	10	17	5	6
Total stockholders equity	2,632	2,487	2,372	2,251	2,604
Total liabilities and stockholders equity	3,228	3,110	2,980	2,690	3,106

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Depreciation and amortization	88	76	83	88	96
Stock-based compensation	129	120	118	115	100
Amortization of operating lease right-of-use assets	11	12	13	15	17
Amortization of premium on investments	0	−3	−860,000	1	1
Provision for doubtful accounts	2	−2	−793,000	5	−3
Deferred income taxes	5	−22	−18	−29	−37
Impairment loss on internally developed software	0	0	16	0	0
Share of net income of equity method investees, net of cash distributions	−707,000	−2	−60,000	—	—
Other non-cash items affecting net income	−1	3	2	−5	−5
Accounts receivable	−18	−29	48	−14	−49
Contract assets, net	17	−9	347,000	6	−21
Inventories	8	−3	−13	−12	17
Operating lease right-of-use assets	−5	−8	−9	266,000	−5
Prepaid expenses and other assets	15	−2	−1	9	17
Accounts payable and other liabilities	23	−35	−52	−34	44
Income taxes, net	−43	−5	−9	8	−3
Contract liabilities	−5	−10	−8	−413,000	2
Operating lease liabilities	−9	−5	−6	−15	−11
Other non-current liabilities	−406,000	−14	3	−5	−16
Net cash provided by operating activities	472	327	367	319	448
Purchases of marketable securities	0	−160	−173	−311	−67
Proceeds from sales of marketable securities	16	234	55	9	11
Proceeds from maturities of available-for-sale securities	0	158	177	109	54
Proceeds from sale of assets	17	0	0	0	16
Purchases of property, plant and equipment	−36	−30	−30	−48	−54
Acquisitions, net of cash acquired	−1	−488	26	−38	−5
Purchases of intangible assets	−6	0	0	−12	0
Purchases of other investments	−75,000	0	0	−5	0
Net cash provided by/(used in) investing activities	−11	−286	54	−296	−45
Proceeds from issuance of common stock	44	40	48	58	122
Repurchase of common stock	−125	−160	−149	−530	−246
Payment of cash dividend	−127	−115	−103	−100	−89
Distribution to controlling interest	−2	−5	−266,000	−1	−7
Payment of Excise Tax on Repurchase of Common Stock	−261,000	0	0	—	—
Purchase of noncontrolling interest in business combinations	0	−10	0	0	—
Equity issued in connection with business combination	0	722,000	0	0	—
Shares repurchased for tax withholdings on vesting of restricted stock	−37	−39	−31	−36	−32
Payments for Deferred Consideration	0	0	500,000	0	0
Net cash used in financing activities	−247	−288	−237	−611	−253
Effect of foreign exchange rate changes on cash and cash equivalents	1	7	5	−17	3
Net increase/(decrease) in cash, cash equivalents, and restricted cash	216	−240	190	−605	153
Cash paid for income taxes, net of refunds received	74	63	61	40	71
Change in property, plant, and equipment purchased, unpaid at period-end	−3	9	4	−1	3
Equity issued in connection with business combination	0	0	21	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro